Published online March 1, 2005
PEDIATRICS Vol. 115 No. 3 March 2005, pp. 681-687 (doi:10.1542/peds.2004-0956)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via ISI Web of Science (12)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gross, S. J.
Right arrow Articles by Mettelman, B. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gross, S. J.
Right arrow Articles by Mettelman, B. B.
Related Collections
Right arrow Premature & Newborn

Follow-up at 15 Years of Preterm Infants From a Controlled Trial of Moderately Early Dexamethasone for the Prevention of Chronic Lung Disease

Steven J. Gross, MD*, Ran D. Anbar, MD* and Barbara B. Mettelman, PhD{ddagger}

* Pediatrics
{ddagger} Psychiatry, State University of New York Upstate Medical University, Syracuse, New York

Objective. Postnatal dexamethasone treatment of ventilator-dependent preterm infants results in rapid improvement in lung function and reduction in chronic lung disease. However, limited data are available on long-term outcomes after such therapy. We studied growth, neurodevelopmental, and pulmonary outcomes at adolescence in children who had participated in a double-blind, placebo-controlled trial of dexamethasone beginning at 2 weeks of age for the prevention of chronic lung disease.

Methods. Thirty-six infants (birth weight ≤1250 g and gestational age ≤30 weeks) who were dependent on mechanical ventilation at 2 weeks of age received a 42-day course of dexamethasone, an 18-day course of dexamethasone, or saline placebo. Twenty-two children survived to 15 years (69% of the 42-day dexamethasone group, 67% of the 18-day dexamethasone group and 45% of the control group), and all were evaluated. Intact survival was defined as survival with normal neurologic examination, IQ >70, and receiving education in the regular classroom.

Results. There were no differences among groups for growth or incidence of neurologic abnormalities. The mean IQ for the 42-day dexamethasone group was 85 ± 10 compared with 60 ± 20 for the 18-day dexamethasone group and 73 ± 23 for the control group. All children in the 42-day dexamethasone group were receiving education in the regular classroom compared with only 50% of the 18-day dexamethasone group and 40% of the control group. As a result, intact survival was significantly greater for the 42-day dexamethasone group (69%) than for either the 18-day dexamethasone group (25%) or the control group (18%). Pulmonary function was significantly better for the 42-day dexamethasone group compared with the 18-day dexamethasone group (eg, forced expiratory volume in 1 second: 90 ± 16 vs 71 ± 15% predicted, respectively).

Conclusion. A 42-day course of dexamethasone therapy beginning at 2 weeks of age in preterm infants who are at high risk for severe chronic lung disease was associated with improved long-term neurodevelopmental outcome. Although additional research is needed to establish the optimal steroid preparation, dosage, and duration of therapy, these data support the view that moderately early (beginning at 1-2 weeks) corticosteroid treatment is advantageous for a select group of ventilator-dependent preterm infants.

Key Words: chronic lung disease • developmental follow-up • postnatal steroid therapy

Abbreviations: FVC, forced vital capacity • FEV1, forced expiratory volume in 1 second • CI, confidence interval

Accepted Jul 26, 2004.




This article has been cited by other articles:


Home page
 PediatricsHome page
A. K. Greene
Corticosteroid Treatment for Problematic Infantile Hemangioma: Evidence Does Not Support an Increased Risk for Cerebral Palsy
Pediatrics, June 1, 2008; 121(6): 1251 - 1252.
[Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
K J Rademaker, L S de Vries, C S P M Uiterwaal, F Groenendaal, D E Grobbee, and F van Bel
Postnatal hydrocortisone treatment for chronic lung disease in the preterm newborn and long-term neurodevelopmental follow-up
Arch. Dis. Child. Fetal Neonatal Ed., January 1, 2008; 93(1): F58 - F63.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
T. M. O'Shea, L. K. Washburn, P. A. Nixon, and D. J. Goldstein
Follow-up of a Randomized, Placebo-Controlled Trial of Dexamethasone to Decrease the Duration of Ventilator Dependency in Very Low Birth Weight Infants: Neurodevelopmental Outcomes at 4 to 11 Years of Age
Pediatrics, September 1, 2007; 120(3): 594 - 602.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
L. W. Doyle, P. G. Davis, C. J. Morley, A. McPhee, J. B. Carlin, and and the DART Study Investigators
Outcome at 2 Years of Age of Infants From the DART Study: A Multicenter, International, Randomized, Controlled Trial of Low-Dose Dexamethasonef
Pediatrics, April 1, 2007; 119(4): 716 - 721.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
L. K. Washburn, P. A. Nixon, and T. M. O'Shea
Follow-up of a Randomized, Placebo-Controlled Trial of Postnatal Dexamethasone: Blood Pressure and Anthropometric Measurements at School Age
Pediatrics, October 1, 2006; 118(4): 1592 - 1599.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
L. R. Ment, B. S. Peterson, J. A. Meltzer, B. Vohr, W. Allan, K. H. Katz, C. Lacadie, K. C. Schneider, C. C. Duncan, R. W. Makuch, et al.
A Functional Magnetic Resonance Imaging Study of the Long-term Influences of Early Indomethacin Exposure on Language Processing in the Brains of Prematurely Born Children
Pediatrics, September 1, 2006; 118(3): 961 - 970.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
R. A. K. Jones and on behalf of the Collaborative Dexamethasone Trial
Randomized, Controlled Trial of Dexamethasone in Neonatal Chronic Lung Disease: 13- to 17-Year Follow-up Study: I. Neurologic, Psychological, and Educational Outcomes
Pediatrics, August 1, 2005; 116(2): 370 - 378.
[Abstract] [Full Text] [PDF]